Seeking Alpha
Long/short equity, insider ownership
Profile| Send Message| ()  

Since my article March 1, titled "3 Stocks With Recent Intensive Insider Buying," the stocks that I featured have performed as follows:

Company

Price 2/28

Price 4/26

Change

Global Geophysical Services (GGS)

$2.34

$3.65

+56.0%

Brookfield Infrastructure Partners (BIP)

$39.65

$38.30

-3.4%

Oiltanking Partners (OILT)

$43.90

$50.51

+15.1%

In this article, I will feature three additional stocks that have seen intensive insider buying during the last 30 days. Intensive insider buying can be defined by the following three criteria:

  1. The stock is purchased by three or more insiders within one month.
  2. The stock is sold by no insiders in the month of intensive purchasing.
  3. At least two purchasers increase their holdings by more than 10%.

1. Strategic Oil & Gas (OTCPK:SOGFF) engages in the exploration and development of petroleum and natural gas reserves in Western Canada.

(click to enlarge)

Insider buying by insider (last 30 days)

  • Cody Smith purchased 50,000 shares on April 17, and currently holds 50,000 shares or less than 0.1% of the company. Cody Smith is Vice President, Operations.
  • Aaron Thompson purchased 13,500 shares on April 17, and currently holds 13,500 shares or less than 0.1% of the company. Aaron Thompson is Chief Financial Officer.
  • Douglas Wright purchased 80,000 shares on April 15, and currently holds 80,000 shares or less than 0.1% of the company. Douglas Wright is Vice President, Business Development.

Insider buying by calendar month

Here is a table of Strategic Oil & Gas' insider trading activity by calendar month.

MonthInsider buying / sharesInsider selling / shares
April 2013143,5000
March 20138,000,0000
February 201300
January 20130158,000

There have been 8,143,500 shares purchased and 158,000 shares sold this year.

Financials

The company reported the full-year 2012 financial results on April 11, with the following highlights:

Revenue$56.5 million
Net loss$4.8 million
Net debt$47.3 million

Outlook

For 2013 Strategic has a capital budget of $75 million that is expected to provide growth in crude oil production and continue to expand the productive boundaries of the Steen River light oil play. The company's production averaged approximately 3,000 Boed during the first quarter of 2013, even with downtime associated with operational and facility constraints.

Second-quarter drilling is anticipated to start in early May. Strategic expects to complete and tie in up to three additional wells in the quarter. Strategic's exit rate guidance for 2013 is 5,000 Boed.

Competition

Oil and gas exploration is intensely competitive in all its phases and involves a high degree of risk. Strategic competes with numerous other participants in the search for, and the acquisition of, oil and natural gas properties and in the marketing of oil and natural gas. Strategic's competitors include oil and natural gas companies that have substantially greater financial resources, staff and facilities than those of Strategic's. Strategic's ability to increase reserves in the future will depend not only on its ability to explore and develop its present properties, but also on its ability to select and acquire suitable producing properties or prospects for exploratory drilling. Competitive factors in the distribution and marketing of oil and natural gas include price and methods and reliability of delivery. Competition may also be presented by alternate fuel sources.

My analysis

There have been three different insiders buying the shares and there have not been any insiders selling the shares during the last 30 days. The management and board own 30.98% of the company. There are nine analyst buy ratings, zero neutral ratings and zero sell ratings, with an average target price of $1.85. The company has a book value of $0.44 per share. The company's 2P reserves are 8,184 Mboe. I have a cautiously bullish bias for the stock currently based on the intensive insider buying.

2. Trimel Pharmaceuticals Corporation (OTC:TRLPF), a specialty pharmaceutical company, engages in developing medications for male hypogonadism, female sexual dysfunction, and various respiratory disorders.

(click to enlarge)

Insider buying by insider (last 30 days)

  • Stephen Gregory purchased 93,700 shares on April 24, pursuant to a public offering. Stephen Gregory currently holds 93,700 shares or less than 0.1% of the company. Stephen Gregory is the Lead Director of the Trimel Board of Directors.
  • Matthew Hawkins purchased 18,700 shares on April 24, pursuant to a public offering. Matthew Hawkins currently holds 18,700 shares or less than 0.1% of the company. Matthew Hawkins serves as Vice President, Legal Affairs and Corporate Secretary.
  • Tommaso Rossi purchased 50,000 shares on April 24, pursuant to a public offering. Tommaso Rossi currently holds 50,000 shares or less than 0.1% of the company. Tommaso Rossi serves as President and Chief Executive Officer of Trimel Pharmaceuticals Corporation.
  • First Generation Capital purchased 18,750,000 shares on April 24, pursuant to a public offering. First Generation Capital currently holds 21,752,500 shares or 15.5% of the company.

Insider buying by calendar month

Here is a table of Trimel's insider trading activity by calendar month.

MonthInsider buying / sharesInsider selling / shares
April 201318,912,4000
March 201300
February 201300
January 201300

The month of April has seen all of the insider buying this year.

Financials

The company reported the full-year 2012 financial results on March 25, with the following highlights:

Revenue$0
Net loss$27.7 million
Cash$9.2 million
Debt$7.1 million

On April 24, 2013, Trimel announced that it had completed its previously announced public offering, for aggregate gross proceeds of $40,000,000. In connection with the offering, the company issued a total of 50,000,000 common shares at a price of $0.80 per common share.

Upcoming milestones

The company has the following upcoming milestones:

ProductUpcoming milestone
CompleoTRTNDA filing expected April 2013
TefinaPhase II results expected H2/2013

Competition

For the 12 months ending December 2012, the total United States hypogonadism market reported sales in excess of $2.1 billion having grown approximately 30% over the previous 12-month period. The current United States competitive landscape for testosterone preparations offers topical products, in both gel and patch presentations, short-acting injectables as well as a buccal patch. In terms of market share, topical gels represent approximately 90% of the total sales volume; the short-acting injectables and topical patch products each represent approximately 5% of the sales volume.

Androgel (Abbvie (ABBV)) is the leading brand in the hypogonadism market, with reported 2012 IMS sales of $1.4 billion. Testim (Auxilium Pharmaceuticals (AUXL)) is second with reported IMS sales of $287 million in 2012. During the course of 2011, the competitive landscape of topical gels in the United States expanded with two new entrants - a third topical testosterone gel marketed by Endo Pharmaceuticals (Fortesta) in March 2011 as well as an underarm topical solution (Axiron) marketed by Eli Lilly (LLY) in April 2011.

My analysis

There have been four different insiders buying the shares and there have not been any insiders selling the shares during the last 30 days. The company just closed a $40 million financing, which should be enough cash to last for the next 12 months. The company has two major catalysts pending for this year. I have a cautiously bullish bias for the stock currently based on the intensive insider buying.

3. Alterra Power (OTCPK:MGMXF) engages in the acquisition, exploration, development, and operation of renewable power projects.

(click to enlarge)

Insider buying by insider (last 30 days)

  • Ross Beaty purchased 15,033,500 shares on April 17, and currently holds 123,833,501 shares or 26.6% of the company. Ross Beaty is Executive Chairman.
  • Lyle Braaten purchased 67,866 shares on April 9, and currently holds 400,000 shares or less than 0.1% of the company. Lyle Braaten is a senior officer of the company.
  • John Carson purchased 68,414 shares on April 9, and currently holds 1,015,000 shares or 0.2% of the company. John Carson is CEO of the company.
  • Walter Segsworth purchased 117,500 shares on April 11-15, and currently holds 1,222,870 shares or 0.3% of the company. Walter Segsworth is a director of the company.

Insider buying by calendar month

Here is a table of Alterra Power's insider trading activity by calendar month.

MonthInsider buying / sharesInsider selling / shares
April 201315,287,2800
March 201355,5550
February 2013030,000
January 2013320,9780

The month of April has seen the most insider buying this year.

Financials

The company reported the full-year 2012 financial results on March 27, with the following highlights:

Revenue$61.1 million
Net loss$20.1 million
Cash$39.2 million
Debt$269.4 million

Competition

Significant competition exists for the limited number of renewable resource opportunities available. As a result of this competition, some of which is with large established companies with substantial capabilities and greater financial and technical resources than Alterra's, Alterra may be unable to acquire additional renewable power operations or properties on acceptable terms.

My Analysis

There have been four different insiders buying the shares and there have not been any insiders selling the shares during the past 30 days. For 2013, the company is projecting $110 million in revenues and EBITDA at $55 million. For 2015, the company is projecting EBITDA of $105 million. The company's book value is $0.61 per share. I have a long position in the stock currently.

Source: 2 Energy Stocks And 1 Biotech With Recent Intensive Insider Buying